AbbVie dans l'actualité
Création de médicaments biopharmaceutiques
Tamtam a trouvé 20 articles récents sur AbbVie.
- AbbVie (ABBV) Pays Out More Than It Earns. How Long Can That Hold?
- AbbVie options flow shows 4:1 call-to-put ratio as stock rises
- AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC
- Update: AbbVie Shares Rise After FDA Gives 2 Breakthrough Designations for Cancer Drug
- AbbVie price target raised to $320 from $280 at Scotiabank
- Should You Buy AbbVie Stock Before Oct. 30?
- AbbVie, Genmab report positive results from Phase III EPCORE DLBCL-2 trial
- Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial
- HSBC Thinks AbbVie Can Climb to $315. Here's the Bull Case in Plain English.
- Better Dividend for Retirees: AbbVie vs. Merck
- Genmab and AbbVie Report Landmark Phase 3 Win for Epcoritamab Combo in Frontline DLBCL
- Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere
- AbbVie (ABBV) vs Bristol Myers (BMY): Which is a Better Stock to Buy?
- Is AbbVie (ABBV) Still Undervalued On FDA Approval And Fresh Pipeline Data?
- AbbVie Just Won FDA Approval for a Once-Daily Parkinson's Pill. Here's Why It Matters More Than You Think.
- AbbVie’s Venetoclax AML Study in Greece: What the Latest Update Means for Investors
- AbbVie to Host Third-Quarter 2026 Earnings Conference Call
- AbbVie long-term data buoys Rinvoq for vitiligo
- BofA Boosts AbbVie and J&J Price Targets on Growth and Pipeline Strength
- AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
Articles collectés par Tamtam et retenus lorsqu'ils portent sur l'entreprise, des plus récents aux plus anciens. Chacun renvoie à sa source.
Vous vendez à des entreprises comme AbbVie ?
Tamtam trouve les entreprises qui correspondent à votre client idéal, analyse chaque compte et vous dit qui contacter, et quand.
Trouver des entreprises similaires